SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- . (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback